EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Feixian Recipe inhibits pulmonary fibrosis by targeting pulmonary microvascular endothelial cells and VEGF/VEGFR2 signaling pathway

Lihong Meng, Chen Wang, Zijuan Wang, Ting Yin, Zhe Liu, Huihui Qin, Yuting Zhang, Xiaofeng Gu, Xiaolin Yu, Liangduo Jiang, Xiaomei Zhang

Traditional Medicine and Modern Medicine · 2018

DOI: 10.1142/s2575900018500052 ↗
AbstractBibliografische Angaben

Abstract

Objective: To investigate the regulatory mechanism of PMVECs and vascular endothelial growth factor VEGF/vascular endothelial growth factor receptor 2 (VEGFR2) signaling pathway in pulmonary fibrosis and the inhibitory effect of Feixian Recipe (FXR) in pulmonary fibrosis by targeting VEGF/VEGFR2 signal pathway. Methods: In this study, pulmonary microvascular endothelial cells (PMVECs) were successfully isolated from rats with pulmonary fibrosis. Cells were divided into six groups: model group, prednisone group, losartan group and three different concentrated (100[Formula: see text]ug/mL, 60[Formula: see text]ug/mL, 20[Formula: see text]ug/mL) FXR groups. The adhesion rate, migration and closed blood vessels of each PMVECs group were detected. The mRNA expression of VEGF, VEGFR2, phosphoinositide 3-kinase (PI3K), mitogen-activated protein kinases 38 (P38 MAPK) and activin receptor-like kinase (ALK) were detected by SYBR Green I real-time fluorescence quantitative PCR. Results: Compared with the model group, the adhesion rate, migration and angiogenesis of PMVECs were decreased in FXR groups ([Formula: see text]). Compared with prednisone and losartan groups, the mRNA expressions of VEGF, VEGFR2, PI3K and P38 MAPK were down-regulated significantly by FXR ([Formula: see text]). Conclution: FXR can inhibit the migration, adhesion and angiogenesis of PMVECs in rats with pulmonary fibrosis by targeting VEGF/VEGFR2 signal pathway, and inhibit the progress of pulmonary fibrosis.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →